Downstream inflammasome mediators

Downstream inflammasome mediators refer to the collective group of signaling molecules and effectors activated following the assembly of an inflammasome complex, such as NLRP3, NLRC4, or AIM2 (Broz & Dixit, Nat Rev Immunol, 2016). The central mediator in this pathway is Caspase-1, a cysteine protease that is recruited to the inflammasome and undergoes auto-catalytic activation. Once active, Caspase-1 performs two critical functions: it proteolytically cleaves the inactive precursors pro-IL-1β and pro-IL-18 into their biologically active, pro-inflammatory forms, and it cleaves Gasdermin D (GSDMD) (Shi et al., Nature, 2015). The N-terminal fragment of GSDMD then translocates to the plasma membrane to form large pores, which facilitate the secretion of cytokines and drive pyroptosis, a highly inflammatory form of programmed cell death (He et al., Sci Rep, 2015). Dysregulation of these downstream mediators is a hallmark of numerous inflammatory and autoinflammatory conditions, including Cryopyrin-Associated Periodic Syndromes (CAPS), gout, and rheumatoid arthritis, as well as chronic diseases like atherosclerosis and type 2 diabetes (Dinarello, Blood, 2011). Because this category is broad and includes multiple distinct proteins, it is often used as a placeholder in drug development pipelines when the specific molecular target (e.g., Caspase-1 vs. IL-1β) is not yet disclosed. Therapeutic intervention typically involves monoclonal antibodies like canakinumab to neutralize IL-1β, or small molecules like belnacasan to inhibit Caspase-1 activity. Recent research has also identified existing drugs like disulfiram as potential inhibitors of Gasdermin D pore formation, offering a novel way to block the final stages of the inflammasome response (Hu et al., Science, 2020).

Other names

Inflammasome signaling componentsCaspase-1 pathwayIL-1 family cytokinesPyroptosis mediatorsInflammasome effectors

Inhibition of Caspase-1 proteolytic activity, neutralization of mature IL-1β or IL-18 cytokines, blockade of IL-1 receptors, or inhibition of Gasdermin D pore formation and pyroptosis.